
Africa’s energy producers are emerging as unexpected long-term beneficiaries of the Middle East conflict, according to oil analysts.
Angola, Mozambique, and Nigeria are among nations increasingly viewed by European and Asian buyers as lower-risk alternatives to disrupted supplies: With the Strait of Hormuz and Red Sea now high-risk routes, African volumes carry lower insurance premiums and more predictable delivery times — structural advantages that could reshape long-term supply contracts.
Africa’s liquefied natural gas sector stands to gain most; export capacity is projected to more than double by 2040, according to the African Energy Chamber. The crisis could also accelerate long-delayed projects, including the Trans-Saharan pipeline designed to carry Nigerian gas through Niger and Algeria to Europe, which has been beset by safety and security concerns in the Sahel region.
Horizon Engage risk analyst Clementine Wallop warned, however, that while Africa was a “logical place to look,” the risks some of these projects have faced — security, political, or logistical in nature — “show that this is not a quick fix.”
Potential gains for producer nations are nevertheless cold comfort for millions of ordinary Africans: The conflict has sent Brent crude surging more than 50% to around $110 a barrel, and since most African countries are net importers of refined oil products, the price shock has been swift and severe.
LATEST POSTS
Addressing sleep apnea early might decrease chances of developing Parkinson's disease
Iran begins cloud seeding to induce rain amid historic drought
Sun storms are powered by a magnetic engine 16 Earths deep, study finds
It's time for Artemis II to break Apollo 13's distance record. What to know about the moon flyby
A Manual for Nations to Head out To
75% of Arab Israelis support Arab party joining government coalition post-war, survey reveals
7 Moves toward a Sound and Dynamic Way of life
Astonishing interstellar comet captured in new images by NASA Mars missions
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug













